Assignee
DRAGONFLY THERAPEUTICS INC
US·14 granted patents·52 pending applications·63 citations·filing 2018–2025
Top patents by PatentIndex Score
66 records- 0197US11939384B1Antibody variable domains targeting the NKG2D receptorDRAGONFLY THERAPEUTICS INC·Filed 2023·Granted Mar 26, 2024·9 cites·16 claims
- 0296US11884733B2Antibody variable domains targeting the NKG2D receptorDRAGONFLY THERAPEUTICS INC·Filed 2019·Granted Jan 30, 2024·10 cites·14 claims
- 0396US11834506B2Multi-specific binding proteins that bind NKG2D, CD16, and a tumor-associated antigen for activation of natural killer cells and therapeutic uses thereof to treat cancerDRAGONFLY THERAPEUTICS INC·Filed 2018·Granted Dec 5, 2023·16 cites·18 claims
- 0496US11787864B2Heterodimeric Fc-fused proteinsDRAGONFLY THERAPEUTICS INC·Filed 2022·Granted Oct 17, 2023·13 cites·13 claims
- 0594US12129300B2Antibody variable domains targeting the NKG2D receptorDRAGONFLY THERAPEUTICS INC·Filed 2023·Granted Oct 29, 2024·1 cites·8 claims
- 0691US11884732B2Proteins binding HER2, NKG2D and CD16DRAGONFLY THERAPEUTICS INC·Filed 2018·Granted Jan 30, 2024·6 cites·15 claims
- 0787US12384847B2Cancer therapy involving an anti-PD1 antibody and a multi-specific binding protein that binds NKG2D, CD16, and a tumor-associated antigenDRAGONFLY THERAPEUTICS INC·Filed 2019·Granted Aug 12, 2025·2 cites·20 claims
- 0887US12264200B2Antibody variable domains targeting the NKG2D receptorDRAGONFLY THERAPEUTICS INC·Filed 2023·Granted Apr 1, 2025·0 cites·18 claims
- 0986US2025019444A1Antibody variable domains targeting the nkg2d receptorDRAGONFLY THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 1085US12157771B2Proteins binding NKG2D, CD16 and CLEC12ADRAGONFLY THERAPEUTICS INC·Filed 2021·Granted Dec 3, 2024·1 cites·21 claims
- 1181US12377144B2Methods of treating cancer using multi-specific binding proteins that bind NKG2D, CD16 and a tumor-associated antigenDRAGONFLY THERAPEUTICS INC·Filed 2022·Granted Aug 5, 2025·1 cites·20 claims
- 1280US2025154261A1Multi-specific binding proteins that bind cd33, nkg2d, and cd16, and methods of useDRAGONFLY THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 1379US12275791B2Multi-specific binding proteins that bind HER2, NKG2D, and CD16, and methods of useDRAGONFLY THERAPEUTICS INC·Filed 2019·Granted Apr 15, 2025·1 cites·6 claims
- 1479US12215157B2Multi-specific binding proteins that bind CD33, NKG2D, and CD16, and methods of useDRAGONFLY THERAPEUTICS INC·Filed 2019·Granted Feb 4, 2025·1 cites·40 claims
- 1576US12384851B2Multi-specific binding proteins that bind BCMA, NKG2D and CD16, and methods of useDRAGONFLY THERAPEUTICS INC·Filed 2019·Granted Aug 12, 2025·1 cites·30 claims
- 1676US2023391877A1Multispecific binding proteins targeting ceaDRAGONFLY THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 1776US2023357409A1Proteins binding nkg2d, cd16 and nectin4DRAGONFLY THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 1875US2023227562A1Combination therapy of cancer involving multi-specific binding proteins that bind nkg2d, cd16, and a tumor-associated antigenDRAGONFLY THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 1975US2023303702A1Combination therapy of cancer involving multi-specific binding proteins that bind nkg2d, cd16, and a tumor-associated antigenDRAGONFLY THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 2074US12378318B2Proteins binding NKG2D, CD16 and a tumor-associated antigenDRAGONFLY THERAPEUTICS INC·Filed 2019·Granted Aug 5, 2025·1 cites·11 claims
- 2174US2024228625A1Proteins binding her2, nkg2d and cd16DRAGONFLY THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 2274US2024166753A1Multi-specific binding proteins that bind nkg2d, cd16, and a tumor-associated antigen for activation of natural killer cells and therapeutic uses thereof to treat cancerDRAGONFLY THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 2373US2024270861A1Proteins binding nkg2d, cd16 and baff-rDRAGONFLY THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 2473US2024360223A1Proteins binding nkg2d, cd16 and baff-rDRAGONFLY THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 2572US2024018266A1Proteins binding cd123, nkg2d and cd16DRAGONFLY THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 2671US2022380459A1Multi-specific binding proteins that bind cd33, nkg2d, and cd16, and methods of useDRAGONFLY THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 2766US2021292420A1Proteins binding nkg2d, cd16 and a tumor-associated antigenDRAGONFLY THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 2865US2021130474A1Multispecific binding proteins targeting caix, ano1, mesothelin, trop2, or claudin-18.2DRAGONFLY THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 2964US2024228645A1Antibodies targeting baff-r and use thereofDRAGONFLY THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 3063US2022089760A1Multi-specific binding proteins that bind bcma, nkg2d and cd16, and methods of useDRAGONFLY THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 3163US2025206827A1Multi-specific binding proteins that bind her2, nkg2d, and cd16, and methods of useDRAGONFLY THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 3260US2023250176A1Ppharmaceutical formulations and therapeutic uses of multi-specific binding proteins that bind egfr, nkg2d, and cd16DRAGONFLY THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 3359US2022119533A1Heterodimeric fc-fused proteinsDRAGONFLY THERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 3459US2021261668A1Proteins binding nkg2d, cd16, and egfr, ccr4, or pd-l1DRAGONFLY THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 3558US2021130496A1Multispecific binding proteins targeting ceaDRAGONFLY THERAPEUTICS INC·Filed 2018·Application pending·0 cites
- 3658US2023220106A1Antibodies targeting 5t4 and uses thereofDRAGONFLY THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 3756US2020277383A1Proteins binding nkg2d, cd16 and a tumor-associated antigenDRAGONFLY THERAPEUTICS INC·Filed 2018·Application pending·0 cites
- 3856US2023416402A1Methods of treating cancer using multi-specific binding proteins that bind nkg2d, cd16, and her2DRAGONFLY THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 3956US2022195065A1Pharmaceutical formulations and dosage regimens for multi-specific binding proteins that bind her2, nkg2d, and cd16 for cancer treatmentDRAGONFLY THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 4055US2023220084A1Antibodies Targeting CLEC12A and Use ThereofDRAGONFLY THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 4155US2023203202A1Proteins binding nkg2d, cd16 and 5t4DRAGONFLY THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 4255US2023257467A1Proteins binding nkg2d, cd16 and egfrDRAGONFLY THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 4354US2023279121A1Antibodies targeting egfr and use thereofDRAGONFLY THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 4453US2020002436A1Proteins binding cd123, nkg2d and cd16DRAGONFLY THERAPEUTICS INC·Filed 2018·Application pending·0 cites
- 4552US2020216544A1Proteins binding nkg2d, cd16, and egfr, hla-e, ccr4, or pd-l1DRAGONFLY THERAPEUTICS INC·Filed 2018·Application pending·0 cites
- 4652US2024117054A1Proteins binding nkg2d, cd16 and flt3DRAGONFLY THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 4752US2024228628A9Antibodies targeting flt3 and use thereofDRAGONFLY THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 4851US2021206859A1Proteins binding nkg2d, cd16 and a tumor-associated antigenDRAGONFLY THERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 4950US2020376034A1Antibody variable domains targeting cd33, and use thereofDRAGONFLY THERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 5050US2021363261A1Protein binding nkg2d, cd16 and a fibroblast activation proteinDRAGONFLY THERAPEUTICS INC·Filed 2019·Application pending·0 cites
Showing the top 50 of 66 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when DRAGONFLY THERAPEUTICS INC files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →